Skip to main content
Top
Published in: Systematic Reviews 1/2018

Open Access 01-12-2018 | Protocol

Nanomedicine for drug delivery in South Africa: a protocol for systematic review

Authors: Trust Saidi, Jill Fortuin, Tania S Douglas

Published in: Systematic Reviews | Issue 1/2018

Login to get access

Abstract

Background

The emergence of nanomedicine in the past decade has changed the landscape of disease diagnosis and treatment. Nanomedicine makes use of nanostructures for applications in different fields of medicine, including drug delivery, biosensors, neuro-electronic interfaces, in vivo imaging, and cell-specific molecular interactions. Despite its relative infancy, nanomedicine has generated a significant body of research as evidenced by peer reviewed literature and several patents. This proposed systematic review will focus specifically on drug delivery systems in which nanoparticles are used to enhance the pharmacological and therapeutic properties of drugs. The strength of nanoparticulate drug delivery systems is their ability to alter the pharmacokinetics and bio-distribution of drugs.
Globally, the discourse on nanomedicine is dominated by research being done in the developed countries of Europe and in the United States of America. Less attention has been given to the applications of nanomedicine in developing countries, particularly Africa. There is dearth of information on the applications of nanomedicine in terms of drug delivery with particular reference to which diseases are being targeted generally in Africa. The review will describe the specific diseases that are being targeted and the progress being made in South Africa, with a view to determining whether the applications of nanomedicine are being appropriated to address the context-specific challenges in this country or if they mimic what is being done globally.

Methods

Keywords related to nanomedicine and drug delivery will be combined to build a search strategy for each of the following databases: PubMed, Cochrane Library (including Cochrane Central Register of Controlled Trials (CENTRAL), Cochrane Database of Systematic Reviews, Cochrane Methodology Register), Google Scholar, NHS Health Technology Assessment Database and Web of Science. We will also check reference lists of included studies for other eligible reports and search unpublished data. To ensure that the search is comprehensive, grey literature will be searched extensively. Literature to be included will have nanomedicine in drug delivery as the primary application and report on the specific diseases that are targeted in South Africa. Two authors will independently screen the search output, select studies and extract data; discrepancies will be resolved by consensus and discussion. When no consensus is reached, the third author will be consulted

Discussion

The systematic review will inform the government, policy-makers, investors, health professionals, scientists, and engineers about the applications of nanomedicine in drug delivery. In particular, it will identify the diseases targeted by the application of nanomedicine for drug delivery and the progress being made in South Africa as the disease burden of this country differs from that of developed countries where nanomedicine has been widely used for drug delivery.

Systematic review registration

Appendix
Available only for authorised users
Literature
1.
go back to reference Riehemann K, Schneider SW, Luger TA, Godin B, Ferrari M, Fuchs H. Nanomedicine--challenge and perspectives. Angew Chemie Int Ed Engl. 2009;48(5):872–97.CrossRef Riehemann K, Schneider SW, Luger TA, Godin B, Ferrari M, Fuchs H. Nanomedicine--challenge and perspectives. Angew Chemie Int Ed Engl. 2009;48(5):872–97.CrossRef
2.
go back to reference Moghimi SM, Hunter AC, Murray JC. Nanomedicine: current status and future prospects. FASEB J. 2005;19(3):311–30.CrossRef Moghimi SM, Hunter AC, Murray JC. Nanomedicine: current status and future prospects. FASEB J. 2005;19(3):311–30.CrossRef
3.
go back to reference Seleci M, Ag Seleci D, Joncyzk R, Stahl F, Blume C, Scheper T. Smart multifunctional nanoparticles in nanomedicine. BioNanoMaterials. 2016;17(1–2):33–41. Seleci M, Ag Seleci D, Joncyzk R, Stahl F, Blume C, Scheper T. Smart multifunctional nanoparticles in nanomedicine. BioNanoMaterials. 2016;17(1–2):33–41.
4.
go back to reference Anderson DG, Burdick JA, Langer R. Materials science. Smart biomaterials. Science. 2004;305(5692):1923–4.CrossRef Anderson DG, Burdick JA, Langer R. Materials science. Smart biomaterials. Science. 2004;305(5692):1923–4.CrossRef
5.
go back to reference Qiu LY, Bae YH. Polymer architecture and drug delivery. Pharm Res. 2006;23(1):1–30.CrossRef Qiu LY, Bae YH. Polymer architecture and drug delivery. Pharm Res. 2006;23(1):1–30.CrossRef
6.
go back to reference Goldberg M, Langer R, Jia X. Nanostructured materials for applications in drug delivery and tissue engineering. J Biomater Sci Poly Ed. 2007;18(3):241–68.CrossRef Goldberg M, Langer R, Jia X. Nanostructured materials for applications in drug delivery and tissue engineering. J Biomater Sci Poly Ed. 2007;18(3):241–68.CrossRef
7.
go back to reference Bhaskar S, Tian F, Stoeger T, Kreyling W, de la Fuente JM, Grazu V, et al. Multifunctional Nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging. Part Fibre Toxicol. 2010;7:3.CrossRef Bhaskar S, Tian F, Stoeger T, Kreyling W, de la Fuente JM, Grazu V, et al. Multifunctional Nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging. Part Fibre Toxicol. 2010;7:3.CrossRef
8.
go back to reference Bhatia S. Natural polymer drug delivery systems: Nanoparticles, plants, and algae; 2016. p. 1–225. Bhatia S. Natural polymer drug delivery systems: Nanoparticles, plants, and algae; 2016. p. 1–225.
9.
go back to reference De Jong WH, Borm PJ. Drug delivery and nanoparticles:applications and hazards. Int J Nanomedicine. 2008;3(2):133–49.CrossRef De Jong WH, Borm PJ. Drug delivery and nanoparticles:applications and hazards. Int J Nanomedicine. 2008;3(2):133–49.CrossRef
10.
go back to reference Mirza AZ, Siddiqui FA. Nanomedicine and drug delivery: a mini review. Int Nano Letters. 2014;4(1):1–7.CrossRef Mirza AZ, Siddiqui FA. Nanomedicine and drug delivery: a mini review. Int Nano Letters. 2014;4(1):1–7.CrossRef
11.
go back to reference Zhang L, Chan JM, Gu FX, Rhee J-W, Wang AZ, Radovic-Moreno AF, et al. Self-assembled lipid− polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano. 2008;2(8):1696–702.CrossRef Zhang L, Chan JM, Gu FX, Rhee J-W, Wang AZ, Radovic-Moreno AF, et al. Self-assembled lipid− polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano. 2008;2(8):1696–702.CrossRef
12.
go back to reference Elzoghby AO, Samy WM, Elgindy NA. Albumin-based nanoparticles as potential controlled release drug delivery systems. J Control Release. 2012;157(2):168–82.CrossRef Elzoghby AO, Samy WM, Elgindy NA. Albumin-based nanoparticles as potential controlled release drug delivery systems. J Control Release. 2012;157(2):168–82.CrossRef
13.
go back to reference Barratt G. Colloidal drug carriers: achievements and perspectives. Cell Mol Life Sci. 2003;60(1):21–37.CrossRef Barratt G. Colloidal drug carriers: achievements and perspectives. Cell Mol Life Sci. 2003;60(1):21–37.CrossRef
14.
go back to reference Nazarov G, Galan S, Nazarova E, Karkishchenko N, Muradov M, Stepanov V. Nanosized forms of drugs (a review). Pharm Chem J. 2009;43(3):163–70.CrossRef Nazarov G, Galan S, Nazarova E, Karkishchenko N, Muradov M, Stepanov V. Nanosized forms of drugs (a review). Pharm Chem J. 2009;43(3):163–70.CrossRef
15.
go back to reference Conti M, Tazzari V, Baccini C, Pertici G, Serino LP, De Giorgi U. Anticancer drug delivery with nanoparticles. In Vivo. 2006;20(6A):697–701.PubMed Conti M, Tazzari V, Baccini C, Pertici G, Serino LP, De Giorgi U. Anticancer drug delivery with nanoparticles. In Vivo. 2006;20(6A):697–701.PubMed
16.
go back to reference Fan Y, Moon JJ. Nanoparticle drug delivery systems designed to improve cancer vaccines and immunotherapy. Vaccine. 2015;3(3):662–85.CrossRef Fan Y, Moon JJ. Nanoparticle drug delivery systems designed to improve cancer vaccines and immunotherapy. Vaccine. 2015;3(3):662–85.CrossRef
17.
go back to reference Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov. 2010;9(8):615–27.CrossRef Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov. 2010;9(8):615–27.CrossRef
18.
19.
go back to reference Vauthier C, Labarre D, Ponchel G. Design aspects of poly (alkylcyanoacrylate) nanoparticles for drug delivery. J Drug Target. 2007;15(10):641–63.CrossRef Vauthier C, Labarre D, Ponchel G. Design aspects of poly (alkylcyanoacrylate) nanoparticles for drug delivery. J Drug Target. 2007;15(10):641–63.CrossRef
20.
go back to reference Cho K, Wang X, Nie S, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res. 2008;14(5):1310–6.CrossRef Cho K, Wang X, Nie S, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res. 2008;14(5):1310–6.CrossRef
21.
go back to reference DePew R. Nanotechnology in global health. Bioengineering Conference (NEBEC), 2014 - 40th Annual Northeast. Boston: IEEE; 2014. DePew R. Nanotechnology in global health. Bioengineering Conference (NEBEC), 2014 - 40th Annual Northeast. Boston: IEEE; 2014.
22.
go back to reference Rediguieri CF. Study on the development of nanotechnology in advanced countries and in Brazil. Braz J Pharm Sci. 2009;45(2):189–200.CrossRef Rediguieri CF. Study on the development of nanotechnology in advanced countries and in Brazil. Braz J Pharm Sci. 2009;45(2):189–200.CrossRef
23.
go back to reference Chang EH, Harford JB, Eaton MA, Boisseau PM, Dube A, Hayeshi R, et al. Nanomedicine: past, present and future–a global perspective. Biochem Biophys Res Commun. 2015;468(3):511–7.CrossRef Chang EH, Harford JB, Eaton MA, Boisseau PM, Dube A, Hayeshi R, et al. Nanomedicine: past, present and future–a global perspective. Biochem Biophys Res Commun. 2015;468(3):511–7.CrossRef
24.
go back to reference Dube A, Ebrahim N. The nanomedicine landscape of South Africa. Nanotechnology Reviews. 2017;6(4):339–44. Dube A, Ebrahim N. The nanomedicine landscape of South Africa. Nanotechnology Reviews. 2017;6(4):339–44.
25.
go back to reference Woodson H, Perrot R. State can cure skewed disease research. BusinessDay; 2017. Woodson H, Perrot R. State can cure skewed disease research. BusinessDay; 2017.
26.
go back to reference Hare JI, Lammers T, Ashford MB, Puri S, Storm G, Barry ST. Challenges and strategies in anti-cancer nanomedicine development: an industry perspective. Adv Drug Deliv Rev. 2017;108:25–38.CrossRef Hare JI, Lammers T, Ashford MB, Puri S, Storm G, Barry ST. Challenges and strategies in anti-cancer nanomedicine development: an industry perspective. Adv Drug Deliv Rev. 2017;108:25–38.CrossRef
27.
go back to reference Mays N, Pope C, Popay J. Systematically reviewing qualitative and quantitative evidence to inform management and policy-making in the health field. J Health Serv Res Policy. 2005;10(1_suppl):6–20.CrossRef Mays N, Pope C, Popay J. Systematically reviewing qualitative and quantitative evidence to inform management and policy-making in the health field. J Health Serv Res Policy. 2005;10(1_suppl):6–20.CrossRef
28.
go back to reference Popay J, Roberts H, Sowden A, Petticrew M, Arai L, Rodgers M, et al. Guidance on the conduct of narrative synthesis in systematic reviews, A product from the ESRC methods programme Version, vol. 1; 2006. p. b92. Popay J, Roberts H, Sowden A, Petticrew M, Arai L, Rodgers M, et al. Guidance on the conduct of narrative synthesis in systematic reviews, A product from the ESRC methods programme Version, vol. 1; 2006. p. b92.
29.
go back to reference Swai H, Semete B, Kalombo L, Chelule P, Kisich K, Sievers B. Nanomedicine for respiratory diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2009;1(3):255–263.PubMed Swai H, Semete B, Kalombo L, Chelule P, Kisich K, Sievers B. Nanomedicine for respiratory diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2009;1(3):255–263.PubMed
30.
go back to reference El-Hussein A, Mfouo-Tynga I, Abdel-Harith M, Abrahamse H. Comparative study between the photodynamic ability of gold and silver nanoparticles in mediating cell death in breast and lung cancer cell lines. J Photochem Photobiol B Biol. 2015;153:67–75.CrossRef El-Hussein A, Mfouo-Tynga I, Abdel-Harith M, Abrahamse H. Comparative study between the photodynamic ability of gold and silver nanoparticles in mediating cell death in breast and lung cancer cell lines. J Photochem Photobiol B Biol. 2015;153:67–75.CrossRef
31.
go back to reference Govender T, Ojewole E, Naidoo P, Mackraj I. Polymeric nanoparticles for enhancing antiretroviral drug therapy. Drug Deliv. 2008;15(8):493–501.CrossRef Govender T, Ojewole E, Naidoo P, Mackraj I. Polymeric nanoparticles for enhancing antiretroviral drug therapy. Drug Deliv. 2008;15(8):493–501.CrossRef
32.
go back to reference Salamanca-Buentello F, Persad DL, Martin DK, Daar AS, Singer PA. Nanotechnology and the developing world. PLoS Med. 2005;2(5):e97.CrossRef Salamanca-Buentello F, Persad DL, Martin DK, Daar AS, Singer PA. Nanotechnology and the developing world. PLoS Med. 2005;2(5):e97.CrossRef
Metadata
Title
Nanomedicine for drug delivery in South Africa: a protocol for systematic review
Authors
Trust Saidi
Jill Fortuin
Tania S Douglas
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Systematic Reviews / Issue 1/2018
Electronic ISSN: 2046-4053
DOI
https://doi.org/10.1186/s13643-018-0823-5

Other articles of this Issue 1/2018

Systematic Reviews 1/2018 Go to the issue